Table 1 (abstract P105). Proportion of Participants in ADVANCE with an Initial Response ≥50%, ≥75% or 100% Reduction in MMD with Sustained Response through to Month 3
From: 16th European Headache Congress 2022 meeting abstracts
From: 16th European Headache Congress 2022 meeting abstracts